Abstract
The striking clinical benefits of intermittent parathyroid hormone in osteoporosis have begun a new era of skeletal anabolic agents. Recombinant human parathyroid hormone (rhPTH) (1-34) is the first US Food and Drug Administration-approved anabolic therapy. Its use has been limited by the need for subcutaneous injection. Newer delivery systems include transdermal and oral preparations. Newer anabolic therapies include monoclonal antibody to sclerostin, a potent inhibitor of osteoblastogenesis; and use of bone morphogenetic proteins and parathyroid hormone-related protein PTHrP, a calcium-regulating hormone similar to PTH.
MeSH terms
-
Adaptor Proteins, Signal Transducing
-
Bone Morphogenetic Proteins / physiology
-
Bone Morphogenetic Proteins / therapeutic use
-
Drug Delivery Systems
-
Genetic Markers / physiology
-
Humans
-
Osteoblasts / drug effects
-
Osteoblasts / physiology
-
Osteoporosis / drug therapy*
-
Parathyroid Hormone / physiology
-
Parathyroid Hormone / therapeutic use*
-
Parathyroid Hormone-Related Protein / therapeutic use
-
Recombinant Proteins / therapeutic use
Substances
-
Adaptor Proteins, Signal Transducing
-
Bone Morphogenetic Proteins
-
Genetic Markers
-
Parathyroid Hormone
-
Parathyroid Hormone-Related Protein
-
Recombinant Proteins
-
SOST protein, human